Henry Ford Health System
henryford.comTotal trials
292
Active
61
Phase 3
17
Total enrollment
125,785
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 38 of 38 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ketorolac | — | — | 7 | ||||
| Celecoxib | — | — | 5 | ||||
| Acetaminophen | — | — | 5 | ||||
| Dexamethasone | — | — | — | — | — | 3 | |
| Bioinductive implant | — | — | — | — | — | 1 | |
| Smith & Nephew Bioinductive Implant | — | — | — | — | — | 1 | |
| Narcotic pain medication | — | — | — | — | — | 1 | |
| Nonnarcotic pain medications | — | — | — | — | — | 1 | |
| Pregabalin | — | — | — | — | — | 1 | |
| Tramadol | — | — | — | — | — | 1 | |
| Ropivicaine | — | — | — | — | — | 1 | |
| Epinephrine | — | — | — | — | — | 1 | |
| Tizanidine | — | — | — | — | — | 1 | |
| Magnesium | — | — | — | — | — | 1 | |
| Oxycodone Hydrochloride 5 Mg | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| Omeprazole | — | — | — | — | — | 1 | |
| Ibuprofen | — | — | — | — | 2 | ||
| Gabapentin | — | — | — | 5 | |||
| Diazepam | — | — | — | 4 | |||
| Hydrocodone-Acetaminophen | — | — | — | — | 3 | ||
| Botulinum Toxin | — | — | — | — | — | 1 | |
| Normal saline | — | — | — | — | — | 1 | |
| Budesonide | — | — | — | — | — | 1 | |
| Tranexamic acid | — | — | — | 4 | |||
| Bortezomib | — | — | — | — | — | 1 | |
| 5-Aminolevulinic acid Hydrochloride | — | — | — | — | — | 1 | |
| Sunscreening Agents | — | — | — | — | — | 1 | |
| Cemiplimab | — | — | — | — | — | 1 | |
| Adjuvant chemotherapy | — | — | — | — | — | 1 | |
| azacitidine | — | — | — | — | — | 1 | |
| onabotulinumtoxinA at a depth of 2mm | — | — | — | — | — | 1 | |
| onabotulinumtoxinA at a depth of 4mm | — | — | — | — | — | 1 | |
| uhCG/EGF | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Sacituzumab govetican | — | — | — | — | — | 1 | |
| Ad5-yCD/mutTKSR39rep-ADP adenovirus and fractionated stereotactic radiosurgery | — | — | — | — | — | 1 | |
| PHARM-PAL2 | — | — | — | — | — | 1 |
Next readouts
- 2020-01-20
- 2021-01-18
- 2022-06
- 2023-06-20
- 2024-12-11
- 2025-09
- 2025-12-30
- 2026-05-17
- 2026-06-30
- 2026-09-15
Top conditions
- Insomnia12
- Pain7
- Coronary Artery Disease7
- Hidradenitis Suppurativa7
- Vitiligo7
- Asthma6
- Ischemic Stroke4
- Healthy4
Frequently asked questions about Henry Ford Health System
- How many clinical trials does Henry Ford Health System have on ClinicalTrials.gov?
- Henry Ford Health System is listed as the lead sponsor on 292 clinical trials in ClinicalTrials.gov, 61 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Henry Ford Health System's trials are in Phase 3?
- 17 of Henry Ford Health System's trials are in Phase 3, spread across 38 active drug programs.
- What therapeutic areas does Henry Ford Health System focus on?
- Henry Ford Health System's most-studied conditions on ClinicalTrials.gov are Insomnia, Pain, Coronary Artery Disease, Hidradenitis Suppurativa, Vitiligo.
- When are Henry Ford Health System's next clinical trial readouts?
- Henry Ford Health System has 10 upcoming primary-completion readouts tracked here; the soonest is “Nonopioid Analgesia After Labral Surgery”, expected around 2020-01-20.